Fulcrum Therapeutics (FULC) Treasury Shares (2018 - 2021)

Fulcrum Therapeutics (FULC) has reported Treasury Shares for 9 consecutive years, with $17.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Treasury Shares fell 75.2% year-over-year to $17.5 million; the TTM figure through Jun 2026 stood at $17.5 million (down 75.2% YoY), while the FY2025 annual figure was $69.5 million, up 161225.22% from the prior year.
• Treasury Shares retreated to $17.5 million in Q2 2026 per FULC's latest filing, from $90.1 million in the prior quarter.
• Across five years, Treasury Shares topped out at $90.1 million in Q1 2026 and bottomed at $43072.0 in Q4 2024.
• Historically, Treasury Shares has averaged $17.7 million across 5 years, with a median of $99858.5 in 2022.
• Annual changes were most pronounced in 2025 — Treasury Shares soared 161225.22% — and 2026, when it slumped 75.2%.
• Fulcrum Therapeutics' Treasury Shares stood at $76718.0 in 2022, then fell by 2.22% to $75017.0 in 2023, then slumped by 42.58% to $43072.0 in 2024, then jumped by 161225.22% to $69.5 million in 2025, then sank by 74.78% to $17.5 million in 2026.
• Business Quant data shows FULC's Treasury Shares at $17.5 million in Q2 2026, $90.1 million in Q1 2026, and $69.5 million in Q4 2025.